MIST Stock Forecast & Price Target

Milestone Pharmaceuticals is well-positioned for growth with the potential launch of their self-administered therapy, Cardamyst for PSVT and expansion into China. While risks exist in regulatory, commercial, intellectual property, and funding areas, the company has secured funding for launch and a phase 3 trial and has potential for $250-300M in peak sales. Improved access and commercial coverage could lead to greater success and significantly benefit their current valuation.

Milestone Pharmaceuticals is a high-risk investment option, with its main product, CARDAMYST, facing multiple challenges. The company's reported revenue is not reflective of its actual demand, as most prescriptions are covered through copay assistance and commercial coverage is limited. Furthermore, while the safety profile of CARDAMYST is clean, its market potential may not be as large as initially projected. The company's profitability depends on the success of its commercialization efforts, creating a funding risk for investors.